Last updated: April 24, 2026
Upsher-Smith v. Glenmark (D. Del.) (1:17-cv-00649): Litigation Summary and Patent-Strategy Analysis
What is the case and what did Upsher-Smith claim?
Upsher-Smith Laboratories, Inc. sued Glenmark Pharmaceuticals Limited in the District of Delaware under the Hatch-Waxman framework for claims tied to Glenmark’s abbreviated new drug application (ANDA) and the marketing of a generic version of Upsher-Smith’s patented product(s). The case is docketed as 1:17-cv-00649.
The record reflects a typical Hatch-Waxman structure: Upsher-Smith asserted patent rights and sought infringement relief and/or statutory remedies triggered by Glenmark’s ANDA filing, while Glenmark defended on non-infringement, invalidity, and any statutory prerequisites.
What procedural posture matters most for valuation and R&D planning?
In Hatch-Waxman, the highest-impact milestones are claim construction, dispositive motions, and any stipulations or final judgment terms that determine market entry timing. For 1:17-cv-00649, the case’s value hinges on three categories of outcomes:
- Which patents were actually asserted and survived early motion practice.
- Whether the litigation produced an ANDA-specific resolution (e.g., non-infringement of asserted claims or invalidity).
- Whether the parties resolved on a settlement that effectively fixed a launch date or design-around scope.
What patents and infringement theories are implicated?
The core allegation in an ANDA case is that Glenmark’s proposed generic product infringes one or more asserted claims of Upsher-Smith’s Orange Book patents. In practice, plaintiffs typically plead infringement under one of two models:
- Literal infringement: claim elements read directly on the proposed generic formulation, dosage form, and/or method claims.
- Infringement by equivalency: minor differences in formulation parameters, process details, or performance characteristics still satisfy claim limitations under doctrine of equivalents.
From a patent-analysis standpoint, the key commercial question is not the existence of infringement theories in the abstract, but which claim limitations are contested and what evidence is used to align those limitations with the ANDA’s “proposed label” and the generic’s manufacturing/formulation documentation.
What did the litigation likely turn on (claim-construction and “ANDA proof”)?
For ANDA cases, the decisive disputes typically track the following technical-to-legal mapping:
- Claim scope interpretation (often done in a Markman ruling): the court construes claim terms, including those tied to concentration ranges, release profiles, particle characteristics, and dosing schedules.
- ANDA teardowns: plaintiffs use the ANDA and/or discovery to show the proposed product meets the claim limitations.
- Indefiniteness and anticipation/obviousness attacks: defendants frequently challenge whether the asserted claims are definite and whether prior art discloses the claimed ranges or methods.
In this case, the litigation’s commercial impact comes from whether the court’s construction narrowed claim scope enough to defeat infringement, or whether the validity record neutralized the asserted patents.
How does this case compare to typical Hatch-Waxman outcomes (what matters for timelines and settlements)?
Which outcomes are most relevant to investors and business planners?
In Hatch-Waxman suits like 1:17-cv-00649, the decision tree usually reduces to four outcomes:
- Final judgment for plaintiff on infringement and validity
- Locks out generic entry during the patent’s effective term (subject to appeals and statutory carve-outs).
- Final judgment for defendant on invalidity
- Clears the way for generic launch, often immediately if no appeal stay.
- Final judgment for defendant on non-infringement
- Often clears launch unless a different claim set remains in force.
- Settlement
- Fixes an entry date and may include design-around or dismissal terms that govern future product iterations.
What is the business meaning of a Markman outcome?
Even before trial, claim construction frequently dictates whether:
- the generic product is “in” or “out” of the claim, and
- the novelty/obviousness narrative survives based on how the claims are narrowed.
For R&D planning, the key is not simply that the court construed terms, but whether the construction aligned with generic design-around opportunities (e.g., different release characteristics, different formulation choices, or different method steps).
What is the practical patent-strategy takeaway for Upsher-Smith and Glenmark?
Upsher-Smith’s likely strategy
Upsher-Smith’s best leverage in these cases is to secure constructions that preserve the breadth of asserted claims and to position the infringement case around measurable properties tied to the ANDA’s disclosures. In practice, Upsher-Smith’s roadmap tends to emphasize:
- a tight claim-to-product mapping (proof that the proposed generic meets every element),
- prior-art distinctions designed to preserve novelty,
- and technical evidence that reduces the defendant’s ability to argue “range overlap” without meeting a specific limitation.
Glenmark’s likely strategy
Glenmark’s best leverage usually comes from:
- narrowing claim scope through claim construction,
- invalidating asserted claims with anticipation or obviousness based on the best prior-art references,
- and attacking definiteness where claim language lacks objective boundaries.
In generic litigation, even a small narrowing can flip outcomes because ANDA submissions are fixed; the defendant can often only change later via new submissions, not via litigation-era product “tweaks.”
What does the case signal about patent strength and enforceability?
The enforceability signal in Hatch-Waxman matters because it predicts whether other Orange Book patents will hold under the same claim-construction and invalidity frameworks.
If the asserted claims were eliminated through invalidity, that suggests:
- the patents likely relied on claim language vulnerable to prior art teaching,
- or the court was willing to treat range disclosures as sufficient to invalidate.
If the asserted claims failed on non-infringement, that suggests:
- the claims were either narrow, or the defendant’s proposed product deviated from critical limitations,
- or the plaintiff’s infringement proof did not align with the proposed generic.
Either path determines how a brand owner budgets future continuations or whether it accelerates new patent filings with improved claim drafting.
Key Takeaways
- 1:17-cv-00649 is a Hatch-Waxman infringement dispute initiated by Upsher-Smith Laboratories, Inc. against Glenmark Pharmaceuticals Limited tied to Glenmark’s ANDA for a generic product covered by Upsher-Smith’s asserted patents.
- The case’s commercial impact in this docket is driven by the standard Hatch-Waxman sequence: asserted patents and surviving claims, claim construction, dispositive motions, and any settlement terms that fix launch timing.
- From a patent-strategy lens, the litigation’s value is determined by whether courts preserved asserted claims through construction and validity, or whether they cleared entry via non-infringement or invalidity.
- For business planning, the actionable lens is how the case outcome informs: (i) Orange Book patent durability under similar constructions, (ii) design-around feasibility for future generic iterations, and (iii) the brand owner’s continuation and claim-drafting priorities.
FAQs
What court and jurisdiction handled 1:17-cv-00649?
The case is in the District of Delaware, docketed as 1:17-cv-00649.
Under what statute type is the dispute governed?
It is a Hatch-Waxman ANDA patent infringement action, typically tied to Orange Book listed patents and a defendant’s ANDA submission.
What are the highest-impact litigation milestones in ANDA cases?
Claim construction (Markman), dispositive motions on infringement/validity, and any settlement terms that affect market entry.
How do outcomes affect generic launch decisions?
A ruling of invalidity or non-infringement clears entry; infringement with validity blocks entry; settlement fixes an entry schedule and may impose design-around constraints.
What does this case tell a patent owner about future filings?
It indicates which claim limitations and evidentiary alignments survive challenge, guiding future continuation strategy and claim drafting to reduce vulnerability to construction and prior-art attacks.
References (APA)
[1] Upsher-Smith Laboratories, Inc. v. Glenmark Pharmaceuticals Limited, No. 1:17-cv-00649 (D. Del. filed 2017).
